Executive Change

Common Shares, Without Par Value   ABT       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549       FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   November 12, 2024 Date of Report (Date of earliest event reported)     ABBOTT LABORATORIES (Exact name of registrant as specified in charter)       Illinois   1-2189   36-0698440 (State or other Jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification No.)       100 Abbott Park Road Abbott Park , Illinois 60064-6400 (Address of principal executive offices)(Zip Code)   Registrant’s telephone number, including area code:  ( 224 ) 667-6100   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨         Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨         Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨         Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨         Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities Registered Pursuant to Section 12(b) of the Act:   Title of Each Class Trading Symbol(s) Name of Each Exchange  on Which Registered Common Shares, Without Par Value ABT New York Stock Exchange Chicago Stock Exchange, Inc.   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company   ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨             Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers   As previously reported, Abbott has Agreements Regarding Change in Control (“Agreements”) with its named executive officers.   The Agreements provide that if Abbott gives notification of extension before the Expiration Date (December 31, 2024), the Agreement’s term shall continue through the second anniversary of the Expiration Date.   On November 12, 2024, Abbott notified the named executive officers that the term of the Agreements was extended through December 31, 2026.         SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.     ABBOTT LABORATORIES     Date: November 15, 2024 By: /s/ Philip P. Boudreau     Philip P. Boudreau     Executive Vice President, Finance and Chief Financial Officer